<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2323">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04357808</url>
  </required_header>
  <id_info>
    <org_study_id>SARCOVID</org_study_id>
    <secondary_id>2020-001634-36</secondary_id>
    <nct_id>NCT04357808</nct_id>
  </id_info>
  <brief_title>Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID)</brief_title>
  <acronym>SARCOVID</acronym>
  <official_title>Randomized Open Pilot Study to Evaluate the Efficacy of Subcutaneous Sarilumab in Patients With Moderate-severe COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maria del Rosario Garcia de Vicuña Pinedo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Investigación Sanitaria Hospital Universitario de la Princesa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The global health emergency created by the rapid spread of the SARS-CoV-2 coronavirus has&#xD;
      pushed healthcare services to face unprecedent challenges to properly manage COVID-19 severe&#xD;
      and critical manifestations affecting a wide population in a short period of time. Clinicians&#xD;
      are committed to do their best with a great uncertainty in this evolving crisis. Off label&#xD;
      use of plenty of drugs has arisen the need for clinical trials to demonstrate their true role&#xD;
      in the therapy. Based in unpublished experiences in China, Italy and Spain, intravenous IL-6&#xD;
      receptor inhibitors are now being tested in several trials but no data on subcutaneous&#xD;
      formulations are available yet. Sarilumab is a human monoclonal antibody that binds&#xD;
      membrane-bound and soluble IL-6 receptors to inhibit IL-6 signalling, licensed in a&#xD;
      subcutaneous route administration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SARCOVID is an investigator-initiated monocentric randomised proof of concept study that aims&#xD;
      to evaluate the efficacy and safety of a single dose of sarilumab, in subcutaneous&#xD;
      administration, in hospitalised patients with moderate to early severe COVID-19 infection,&#xD;
      compared to the current standard of care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 13, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised, open-label, single-center, comparative trial of sarilumab plus standard of care vs. standard of care in a 2:1 ratio.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in clinical status assessment using the 7-point ordinal scale at day 7 after randomisation</measure>
    <time_frame>7 days from enrolment</time_frame>
    <description>Score ranges 1-7&#xD;
Death;&#xD;
Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO);&#xD;
Hospitalized, requiring non-invasive ventilation or high flow oxygen devices;&#xD;
Hospitalized, requiring supplemental oxygen;&#xD;
Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care&#xD;
Not hospitalized</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of hospitalisation (days)</measure>
    <time_frame>30 days from enrolment</time_frame>
    <description>Days from the date of enrolment to the date of discharge</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>30 days from enrolment</time_frame>
    <description>Number of deaths</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to become afebrile (days)</measure>
    <time_frame>30 days from enrolment</time_frame>
    <description>Time to become afebrile for a minimum period of 48 hours, without antipyretics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to non-invasive mechanical ventilation (days)</measure>
    <time_frame>30 days from enrolment</time_frame>
    <description>Days from enrolment to non-invasive mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to invasive mechanical ventilation (days)</measure>
    <time_frame>30 days from enrolment</time_frame>
    <description>Days from enrolment to invasive mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to independence from supplementary oxygen therapy (days)</measure>
    <time_frame>30 days from enrolment</time_frame>
    <description>Days from enrolment to supplementary oxygen therapy withdrawal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in clinical status assessment using the 7-point ordinal scale at day 14 after randomisation</measure>
    <time_frame>14 days from enrolment</time_frame>
    <description>Scale ranges 1-7:&#xD;
Death&#xD;
Hospitalized, with mechanical ventilation or extracorporeal membrane oxygenation (ECMO).&#xD;
Hospitalized, with non-invasive mechanical ventilation, a mask with a reservoir or oxygen with high flow nasal goggles.&#xD;
Hospitalized with oxygen supplement&#xD;
Hospitalized, without oxygen supplement, but in need of continued medical care (related or not with COVID)&#xD;
Hospitalized, without oxygen supplement and without the need for continued medical care&#xD;
Not hospitalized</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of serious and non-serious adverse events.</measure>
    <time_frame>30 days after enrolment</time_frame>
    <description>Number of adverse events and number of patients with adverse events</description>
  </other_outcome>
  <other_outcome>
    <measure>Discontinuation due to adverse reactions</measure>
    <time_frame>30 days after enrolment</time_frame>
    <description>Number of adverse reactions that requires discontinuation of any drug in the study</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Covid-19</condition>
  <arm_group>
    <arm_group_label>Sarilumab plus standard of care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sarilumab 200 mg, 2 sc injections in pre-filled syringe or pen, single dose. Treatment with drugs or procedures in routine clinical practice that the clinician responsible for the patient deems necessary is allowed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with drugs or procedures in routine clinical practice</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sarilumab</intervention_name>
    <description>Single dose treatment with sarilumab 2 x 200 mg subcutaneously</description>
    <arm_group_label>Sarilumab plus standard of care</arm_group_label>
    <other_name>Kevzara</other_name>
    <other_name>SAR153191</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standar of care</intervention_name>
    <description>Usual clinical care</description>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt; 18 years&#xD;
&#xD;
          -  Laboratory-confirmed SARS-CoV-2 infection as determined by PCR or other validated&#xD;
             commercial or public health assay&#xD;
&#xD;
          -  Documented interstitial pneumonia requiring admission and at least two of the&#xD;
             following:&#xD;
&#xD;
               1. Fever ≥ 37.8ºC (tympanic)&#xD;
&#xD;
               2. IL-6 in serum ≥ 25 ng / mL (in the absence of a previous dose of prednisone or&#xD;
                  equivalent&gt; 1 mg / kg) or PCR&gt; 5mg / dL&#xD;
&#xD;
               3. Lymphocytes &lt;600 mm3&#xD;
&#xD;
               4. Ferritin&gt; 300 mcg / L that doubles in 24 hours&#xD;
&#xD;
               5. Ferritin&gt; 600 mcg / L in the first determination and LDH&gt; 250 U / L&#xD;
&#xD;
               6. D-dimer (&gt; 1 mg / L)&#xD;
&#xD;
          -  Informed verbal or administration consent under urgent conditions, documented in the&#xD;
             electronic medical record.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who require mechanical ventilation at the time of inclusion.&#xD;
&#xD;
          -  AST / ALT values &gt; 5 folds upper normal limit.&#xD;
&#xD;
          -  Neutrophil count below 500 cells / mm3&#xD;
&#xD;
          -  Platelet count below 50,000 cells / mm3&#xD;
&#xD;
          -  Documented sepsis or high suspicion by pathogens other than COVID-19.&#xD;
&#xD;
          -  Presence of comorbidities that according to clinical judgment could lead to an&#xD;
             unfavorable result.&#xD;
&#xD;
          -  Complicated diverticulitis or intestinal perforation.&#xD;
&#xD;
          -  Current skin infection (eg, uncontrolled dermopiodermitis).&#xD;
&#xD;
          -  Immunosuppressive anti-rejection therapy.&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  Previous treatment with tocilizumab or sarilumab.&#xD;
&#xD;
          -  Patients participating in some other clinical trial for SARS-CoV-2 infection.&#xD;
&#xD;
          -  Patients with known hypersensitivity or contraindication to sarilumab or excipients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosario Garcia de Vicuña, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>November 8, 2020</last_update_submitted>
  <last_update_submitted_qc>November 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</investigator_affiliation>
    <investigator_full_name>Maria del Rosario Garcia de Vicuña Pinedo</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>COVID</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>coronavirus infections</keyword>
  <keyword>sarilumab</keyword>
  <keyword>IL-6 receptor inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

